Compare CHGG & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGG | UNCY |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 121.9M |
| IPO Year | 2013 | 2021 |
| Metric | CHGG | UNCY |
|---|---|---|
| Price | $0.94 | $6.23 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $1.42 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 1.7M | 384.0K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $3.71 |
| 52 Week High | $2.40 | $11.00 |
| Indicator | CHGG | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 57.10 |
| Support Level | $0.83 | $6.31 |
| Resistance Level | $0.99 | $6.95 |
| Average True Range (ATR) | 0.08 | 0.42 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 56.50 | 53.72 |
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.